These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 32237123)

  • 21. 3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer.
    Shiraishi A; Oh-Hara T; Takahashi Y; Uchibori K; Nishio M; Katayama R
    Biochem Biophys Res Commun; 2024 Sep; 725():150255. PubMed ID: 38897043
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
    Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
    Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Induction of apoptosis by tumor suppressor FHIT via death receptor signaling pathway in human lung cancer cells.
    Deng WG; Nishizaki M; Fang B; Roth JA; Ji L
    Biochem Biophys Res Commun; 2007 Apr; 355(4):993-9. PubMed ID: 17328863
    [TBL] [Abstract][Full Text] [Related]  

  • 24. FHIT, EGFR, and MSH2: possible etiopathologic, prognostic, and predictive role in non-small cell lung carcinoma in Egyptian patients.
    Younes SF; Aiad HA; Asaad NY; Kandil MA; Natkunam Y; Mokhtar NM
    Appl Immunohistochem Mol Morphol; 2014 Apr; 22(4):275-83. PubMed ID: 24185125
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
    Wu X; Wu G; Yao X; Hou G; Jiang F
    Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Assessment of the prognostic value of methylation status and expression levels of FHIT, GSTP1 and p16 in non-small cell lung cancer in Egyptian patients.
    Haroun RA; Zakhary NI; Mohamed MR; Abdelrahman AM; Kandil EI; Shalaby KA
    Asian Pac J Cancer Prev; 2014; 15(10):4281-7. PubMed ID: 24935385
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Restoration of fragile histidine triad (FHIT) expression induces apoptosis and suppresses tumorigenicity in lung and cervical cancer cell lines.
    Roz L; Gramegna M; Ishii H; Croce CM; Sozzi G
    Proc Natl Acad Sci U S A; 2002 Mar; 99(6):3615-20. PubMed ID: 11891319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Frequent allelic deletion at the FHIT locus associated with p53 overexpression in squamous cell carcinoma subtype of Taiwanese non-small-cell lung cancers.
    Lee YC; Wu CT; Shih JY; Jou YS; Chang YL
    Br J Cancer; 2004 Jun; 90(12):2378-83. PubMed ID: 15150628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative Measurement of HER2 Expression in Non-Small Cell Lung Cancer With a High-Sensitivity Assay.
    Liu M; Vathiotis I; Robbins CJ; Chan NNN; Moutafi M; Burela S; Xirou V; Schalper KA; Herbst RS; Syrigos K; Rimm DL
    Mod Pathol; 2024 Sep; 37(9):100556. PubMed ID: 38964502
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An increase in BAG-1 by PD-L1 confers resistance to tyrosine kinase inhibitor in non-small cell lung cancer via persistent activation of ERK signalling.
    Lin PL; Wu TC; Wu DW; Wang L; Chen CY; Lee H
    Eur J Cancer; 2017 Nov; 85():95-105. PubMed ID: 28892778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The apoptotic pathway triggered by the Fhit protein in lung cancer cell lines is not affected by Bcl-2 or Bcl-x(L) overexpression.
    Roz L; Andriani F; Ferreira CG; Giaccone G; Sozzi G
    Oncogene; 2004 Dec; 23(56):9102-10. PubMed ID: 15489891
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic value of FHIT, CTNNB1, and MUC1 expression in non-small cell lung cancer.
    Woenckhaus M; Merk J; Stoehr R; Schaeper F; Gaumann A; Wiebe K; Hartmann A; Hofstaedter F; Dietmaier W
    Hum Pathol; 2008 Jan; 39(1):126-36. PubMed ID: 17949785
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FHIT and p53 status and response to platinum-based treatment in advanced non-small cell lung cancer.
    Cortinovis DL; Andriani F; Livio A; Fabbri A; Perrone F; Marcomini B; Pilotti S; Mariani L; Bidoli P; Bajetta E; Roz L; Sozzi G
    Curr Cancer Drug Targets; 2008 Aug; 8(5):342-8. PubMed ID: 18690840
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fhit expression protects against HER2-driven breast tumor development: unraveling the molecular interconnections.
    Bianchi F; Tagliabue E; Ménard S; Campiglio M
    Cell Cycle; 2007 Mar; 6(6):643-6. PubMed ID: 17374991
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tripartite motif-containing 37 (TRIM37) promotes the aggressiveness of non-small-cell lung cancer cells by activating the NF-κB pathway.
    Li Y; Deng L; Zhao X; Li B; Ren D; Yu L; Pan H; Gong Q; Song L; Zhou X; Dai T
    J Pathol; 2018 Nov; 246(3):366-378. PubMed ID: 30043491
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.
    Leech AO; Vellanki SH; Rutherford EJ; Keogh A; Jahns H; Hudson L; O'Donovan N; Sabri S; Abdulkarim B; Sheehan KM; Kay EW; Young LS; Hill ADK; Smith YE; Hopkins AM
    Breast Cancer Res; 2018 Nov; 20(1):140. PubMed ID: 30458861
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Ectogenous fragile histidine triad gene inhibits the malignant phenotype of human lung cancer cell line A549 in vitro and in vivo].
    Zhang LQ; Wang H; Lai BT; Yue WT; Zhan XP; Yang XH; Zhang CY; Zhang TM
    Zhonghua Jie He He Hu Xi Za Zhi; 2005 May; 28(5):333-6. PubMed ID: 15949315
    [TBL] [Abstract][Full Text] [Related]  

  • 38. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
    Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
    Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Loss of FHIT protein expression is related to high proliferation, low apoptosis and worse prognosis in non-small-cell lung cancer.
    Toledo G; Sola JJ; Lozano MD; Soria E; Pardo J
    Mod Pathol; 2004 Apr; 17(4):440-8. PubMed ID: 14976524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fhit delocalizes annexin a4 from plasma membrane to cytosol and sensitizes lung cancer cells to paclitaxel.
    Gaudio E; Paduano F; Spizzo R; Ngankeu A; Zanesi N; Gaspari M; Ortuso F; Lovat F; Rock J; Hill GA; Kaou M; Cuda G; Aqeilan RI; Alcaro S; Croce CM; Trapasso F
    PLoS One; 2013; 8(11):e78610. PubMed ID: 24223161
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.